Pulmonology Xagena
Data were reported from across AstraZeneca’s industry-leading lung cancer portfolio at the World Conference on Lung Cancer ( WCLC ) 2015, in Denver, Colorado ( U.S. ). 25 abstracts ( including 9 oral ...
Small-cell lung cancer ( SCLC ) is an aggressive lung cancer with high rate of relapse following initial treatment; immunotherapy holds potential as a novel treatment option for this disease. The an ...
The phase 2 ATLANTIC study has investigated the anti-PD-L1 antibody Durvalumab ( Imfinzi ) in heavily pretreated patients with advanced non-small cell lung cancer ( NSCLC ). Researchers have repor ...
